Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5‐year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan a...

Full description

Saved in:
Bibliographic Details
Published in:Internal medicine journal 2018-06, Vol.48 (6), p.637-644
Main Authors: Pokorny, Adrian M. J., Chin, Venessa T., Nagrial, Adnan M., Yip, Desmond, Chantrill, Lorraine A.
Format: Article
Language:English
Subjects:
5-Fluorouracil
Adenocarcinoma
cancer genomics
clinical trials
cytotoxic chemotherapy
Cytotoxicity
Folinic acid
Gemcitabine
Immunotherapy
Irinotecan
Metastases
Metastasis
metastatic
Oxaliplatin
Paclitaxel
Pancreatic cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5‐year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab‐paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental. This review discusses the evidence behind the currently used regimens, while introducing the potential future of pancreatic cancer care.
ISSN:1444-0903
1445-5994
DOI:10.1111/imj.13810